Physician profile
Gregory J Healey
NPI 1558372086
$7,037.14
in general payments reported to CMS, 2019-2025
50 companies · $1,461 in 2025
The $1,461 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $866 · 2020: $266 · 2021: $595 · 2022: $1,033 · 2023: $1,445 · 2024: $1,371 · 2025: $1,461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,177.79 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,391.77 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $670.78 | 2019-2025 | |
| Novo Nordisk INC | $605.59 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $391.62 | 2019-2025 | |
| Glaxosmithkline, LLC. | $381.07 | 2019-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $231.10 | 2023-2025 | Auvelity |
| Amgen INC. | $218.46 | 2020-2025 | Otezla, Repatha, Repatha |
| Merck Sharp & Dohme LLC | $217.24 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $198.95 | 2022-2023 | |
| Allergan, INC. | $172.05 | 2019 | |
| Alkermes, INC. | $162.72 | 2022-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $162.12 | 2023-2025 | Rexulti, Vyepti |
| Novartis Pharmaceuticals Corporation | $160.70 | 2019-2023 | |
| Lilly USA, LLC | $158.15 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Otsuka America Pharmaceutical, INC. | $155.90 | 2022-2025 | Rexulti, Jynarque |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Healey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.